Heart Failure Device Trials Lack Risk “Trade-Off” Data – CDRH’s Zuckerman
This article was originally published in The Gray Sheet
Executive Summary
Heart failure device trials should be powered to measure differences in mortality compared with the control, even if mortality reduction is not the therapy's primary goal, according to CDRH Cardiovascular Devices Branch Chief Bram Zuckerman, MD